199 related articles for article (PubMed ID: 19738020)
1. Influence of inoculum size and marbofloxacin plasma exposure on the amplification of resistant subpopulations of Klebsiella pneumoniae in a rat lung infection model.
Kesteman AS; Ferran AA; Perrin-Guyomard A; Laurentie M; Sanders P; Toutain PL; Bousquet-Mélou A
Antimicrob Agents Chemother; 2009 Nov; 53(11):4740-8. PubMed ID: 19738020
[TBL] [Abstract][Full Text] [Related]
2. Pharmacodynamics of the new des-f(6)-quinolone garenoxacin in a murine thigh infection model.
Andes D; Craig WA
Antimicrob Agents Chemother; 2003 Dec; 47(12):3935-41. PubMed ID: 14638504
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic/pharmacodynamic analysis of the influence of inoculum size on the selection of resistance in Escherichia coli by a quinolone in a mouse thigh bacterial infection model.
Ferran AA; Kesteman AS; Toutain PL; Bousquet-Mélou A
Antimicrob Agents Chemother; 2009 Aug; 53(8):3384-90. PubMed ID: 19487439
[TBL] [Abstract][Full Text] [Related]
4. Enrichment of fluoroquinolone-resistant Staphylococcus aureus: oscillating ciprofloxacin concentrations simulated at the upper and lower portions of the mutant selection window.
Firsov AA; Lubenko IY; Smirnova MV; Strukova EN; Zinner SH
Antimicrob Agents Chemother; 2008 Jun; 52(6):1924-8. PubMed ID: 18378704
[TBL] [Abstract][Full Text] [Related]
5. In Vivo Pharmacodynamic Target Assessment of Delafloxacin against Staphylococcus aureus, Streptococcus pneumoniae, and Klebsiella pneumoniae in a Murine Lung Infection Model.
Lepak AJ; Andes DR
Antimicrob Agents Chemother; 2016 Aug; 60(8):4764-9. PubMed ID: 27216072
[TBL] [Abstract][Full Text] [Related]
6. In vivo pharmacodynamic efficacy of gatifloxacin against Streptococcus pneumoniae in an experimental model of pneumonia: impact of the low levels of fluoroquinolone resistance on the enrichment of resistant mutants.
Croisier D; Etienne M; Piroth L; Bergoin E; Lequeu C; Portier H; Chavanet P
J Antimicrob Chemother; 2004 Sep; 54(3):640-7. PubMed ID: 15317743
[TBL] [Abstract][Full Text] [Related]
7. In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus.
Firsov AA; Vostrov SN; Lubenko IY; Drlica K; Portnoy YA; Zinner SH
Antimicrob Agents Chemother; 2003 May; 47(5):1604-13. PubMed ID: 12709329
[TBL] [Abstract][Full Text] [Related]
8. Pharmacodynamics of the new fluoroquinolone gatifloxacin in murine thigh and lung infection models.
Andes D; Craig WA
Antimicrob Agents Chemother; 2002 Jun; 46(6):1665-70. PubMed ID: 12019073
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic and pharmacodynamic testing of marbofloxacin administered as a single injection for the treatment of bovine respiratory disease.
Vallé M; Schneider M; Galland D; Giboin H; Woehrlé F
J Vet Pharmacol Ther; 2012 Dec; 35(6):519-28. PubMed ID: 22126438
[TBL] [Abstract][Full Text] [Related]
10. In vitro Dynamic Pharmacokinetic/Pharmacodynamic (PK/PD) study and COPD of Marbofloxacin against Haemophilus parasuis.
Sun J; Xiao X; Huang RJ; Yang T; Chen Y; Fang X; Huang T; Zhou YF; Liu YH
BMC Vet Res; 2015 Dec; 11():293. PubMed ID: 26626889
[TBL] [Abstract][Full Text] [Related]
11. Searching for the Optimal Predictor of Ciprofloxacin Resistance in Klebsiella pneumoniae by Using In Vitro Dynamic Models.
Strukova EN; Portnoy YA; Romanov AV; Edelstein MV; Zinner SH; Firsov AA
Antimicrob Agents Chemother; 2015 Dec; 60(3):1208-15. PubMed ID: 26643328
[TBL] [Abstract][Full Text] [Related]
12. Comparative mutant prevention concentration and mechanism of resistance to veterinary fluoroquinolones in Staphylococcus pseudintermedius.
Awji EG; Tassew DD; Lee JS; Lee SJ; Choi MJ; Reza MA; Rhee MH; Kim TH; Park SC
Vet Dermatol; 2012 Aug; 23(4):376-80, e68-9. PubMed ID: 22409306
[TBL] [Abstract][Full Text] [Related]
13. Pharmacodynamic assessment based on mutant prevention concentrations of fluoroquinolones to prevent the emergence of resistant mutants of Streptococcus pneumoniae.
Homma T; Hori T; Sugimori G; Yamano Y
Antimicrob Agents Chemother; 2007 Nov; 51(11):3810-5. PubMed ID: 17664314
[TBL] [Abstract][Full Text] [Related]
14. Emergence of resistant Streptococcus pneumoniae in an in vitro dynamic model that simulates moxifloxacin concentrations inside and outside the mutant selection window: related changes in susceptibility, resistance frequency and bacterial killing.
Zinner SH; Lubenko IY; Gilbert D; Simmons K; Zhao X; Drlica K; Firsov AA
J Antimicrob Chemother; 2003 Oct; 52(4):616-22. PubMed ID: 12951352
[TBL] [Abstract][Full Text] [Related]
15. In vivo validation of the mutant selection window hypothesis with moxifloxacin in a murine model of tuberculosis.
Almeida D; Nuermberger E; Tyagi S; Bishai WR; Grosset J
Antimicrob Agents Chemother; 2007 Dec; 51(12):4261-6. PubMed ID: 17938193
[TBL] [Abstract][Full Text] [Related]
16. Using In Vitro Dynamic Models To Evaluate Fluoroquinolone Activity against Emergence of Resistant Salmonella enterica Serovar Typhimurium.
Lee SJ; Awji EG; Park NH; Park SC
Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27895011
[TBL] [Abstract][Full Text] [Related]
17. Activities of mutant prevention concentration-targeted moxifloxacin and levofloxacin against Streptococcus pneumoniae in an in vitro pharmacodynamic model.
Allen GP; Kaatz GW; Rybak MJ
Antimicrob Agents Chemother; 2003 Aug; 47(8):2606-14. PubMed ID: 12878526
[TBL] [Abstract][Full Text] [Related]
18. Evaluating the optimal time for amikacin administration with respect to haemodialysis using an in vitro pharmacodynamic simulation against epidemic nosocomial OXA-48 producing Klebsiella pneumoniae ST405 strains.
Carcas AJ; Sevillano D; González N; Alou L; Gómez-Gil R; Muñoz M; Llanos L; Sanchez-Villanueva RJ; Gonzalez-Parra E; Giménez MJ; Aguilar L
J Glob Antimicrob Resist; 2019 Dec; 19():241-251. PubMed ID: 31176754
[TBL] [Abstract][Full Text] [Related]
19. Pharmacodynamic and pharmacokinetic profiling of delafloxacin in a murine lung model against community-acquired respiratory tract pathogens.
Thabit AK; Crandon JL; Nicolau DP
Int J Antimicrob Agents; 2016 Nov; 48(5):535-541. PubMed ID: 27742208
[TBL] [Abstract][Full Text] [Related]
20. Mutant-prevention concentration and mechanism of resistance in clinical isolates and enrofloxacin/marbofloxacin-selected mutants of Escherichia coli of canine origin.
Gebru E; Choi MJ; Lee SJ; Damte D; Park SC
J Med Microbiol; 2011 Oct; 60(Pt 10):1512-1522. PubMed ID: 21596912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
